Biotech ETF Rises 17% in a Month Without NVIDIA
A biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
Explore affordable index funds for retirement and learn how low fees can boost your long-term gains. This intro covers selection basics and cost considerations.
23,808 articlesA biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
A contrarian, anti-ESG energy ETF seeks to profit from oil-price volatility by concentrating on top fossil-fuel produ...
As IPO activity spikes, investors wonder if history is rhyming with 1929 and 2000. This guide breaks down the signals...
Retail traders drove a large share of leveraged ETF activity in late 2025 as markets swung. This piece examines the p...
Phantom’s strategic pivot toward leveraged derivatives signals a new era for Solana users. This guide unpacks what it...
Analysts see SpaceX, OpenAI, and Anthropic pursuing record mega-IPOs in 2026, potentially reshaping liquidity for ven...
A focused infrastructure fund rode the AI build-out to roughly 28% gains through mid-2026, underscoring how concentra...
Gold flirts with bear-market as risk appetite wobbles amid rising rates and Middle East tensions. Traders weigh margi...
ARTY leads humanoid-robot ETFs in 2026, outpacing BOTT and ROBO as investors chase AI software momentum. This shift h...
Is XRP still worth considering today? This guide dives into timing, risk, and practical entry strategies for investor...
Warren Buffett's successor, Greg Abel, is drawing new attention as recent 13F filings hint at a shift in Berkshire's ...
A single roast joke and a social post can ripple into real financial consequences for celebrities and fans alike. Thi...